Technical Analysis for EYES - Second Sight Medical Products, Inc.

Grade Last Price % Change Price Change
grade C 0.85 2.13% 0.02
EYES closed up 2.13 percent on Friday, March 22, 2019, on 1.45 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical EYES trend table...

Date Alert Name Type % Chg
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Pocket Pivot Bullish Swing Setup 0.00%
Mar 21 Overbought Stochastic Strength 2.13%
Mar 20 Overbought Stochastic Strength 1.19%
Mar 19 Pocket Pivot Bullish Swing Setup -1.36%
Mar 19 Stochastic Reached Overbought Strength -1.36%
Mar 19 Overbought Stochastic Strength -1.36%
Mar 19 Up 3 Days in a Row Strength -1.36%
Mar 19 Upper Bollinger Band Touch Strength -1.36%
Mar 18 Pocket Pivot Bullish Swing Setup 1.14%

Older signals for EYES ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Second Sight Medical Products, Inc. was founded in 1998 with a mission to restore vision to the blind. Today, Second Sight’s Argus II retinal prosthesis provides functional vision to patients blinded by outer retinal degenerations such as retinitis pigmentosa. The company’s innovative technology is the only retinal prosthesis approved by the United States FDA and the first device to receive a CE mark in Europe. The company’s transformative prosthetic device allows blind individuals to gain greater independence in their daily lives. Second Sight believes that its award winning technology will serve as a platform to treat nearly all forms of blindness and could be extended to other neurostimulation applications beyond vision restoration. The Argus II system is currently available in the US and Europe and the company is actively pursuing additional geographic markets. With next generation products under development, the company plans to continue developing, manufacturing and marketing its innovative visual prostethics around the world. Second Sight’s US Headquarters are in Sylmar, California. European Headquarters are in Lausanne, Switzerland.
Medicine Biotechnology Emerging Technologies Medical Devices FDA Retinitis Pigmentosa Vision Biomedical Engineering Blindness Neuroprosthetics Neurostimulation
Is EYES a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.25
52 Week Low 0.635
Average Volume 379,762
200-Day Moving Average 1.334
50-Day Moving Average 0.7934
20-Day Moving Average 0.79
10-Day Moving Average 0.822
Average True Range 0.0568
ADX 20.0
+DI 23.6345
-DI 18.9655
Chandelier Exit (Long, 3 ATRs ) 0.7096
Chandelier Exit (Short, 3 ATRs ) 0.8404
Upper Bollinger Band 0.896
Lower Bollinger Band 0.684
Percent B (%b) 0.78
BandWidth 26.835443
MACD Line 0.0164
MACD Signal Line 0.0074
MACD Histogram 0.009
Fundamentals Value
Market Cap 48.27 Million
Num Shares 56.8 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -1.20
Price-to-Sales 12.04
Price-to-Book 3.29
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.92
Resistance 3 (R3) 0.92 0.89 0.91
Resistance 2 (R2) 0.89 0.87 0.89 0.91
Resistance 1 (R1) 0.87 0.86 0.88 0.87 0.90
Pivot Point 0.84 0.84 0.85 0.84 0.84
Support 1 (S1) 0.82 0.82 0.83 0.83 0.80
Support 2 (S2) 0.79 0.81 0.80 0.79
Support 3 (S3) 0.77 0.79 0.79
Support 4 (S4) 0.78